Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Misfolded lens proteins—primarily crystallins such as α-, β-, and γ-crystallin—are structural proteins in the lens that, when destabilized by mutations or post-translational modifications (oxidation, truncation, deamidation), lose their normal soluble, transparent state and aggregate to form light-scattering opacities characteristic of cataract[1][3][6]. α-crystallin also functions as a molecular chaperone, sequestering misfolded proteins; when overwhelmed or mutated, aggregation is accelerated, leading to further lens opacification and sometimes cell death[1][2][5]. The process is central to cataract pathogenesis, but "misfolded lens proteins" describes a phenotype rather than a discrete, druggable molecular entity or validated therapeutic target[3]. Thus, it is not a canonical target but rather a pathogenic state or consequence of damaged crystallin homeostasis.
None standard; experimental strategies aim to prevent aggregation, stabilize folding, or enhance clearance
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Crystallin protein (misfolded form).